4Front Ventures Past Earnings Performance
Past criteria checks 0/6
4Front Ventures has been growing earnings at an average annual rate of 32.8%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 19.3% per year.
Key information
32.8%
Earnings growth rate
42.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 19.3% |
| Return on equity | n/a |
| Net Margin | -46.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How 4Front Ventures makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 76 | -35 | 47 | 0 |
| 30 Jun 24 | 81 | -55 | 59 | 0 |
| 31 Mar 24 | 90 | -55 | 61 | 0 |
| 31 Dec 23 | 97 | -45 | 63 | 0 |
| 30 Sep 23 | 104 | -51 | 68 | 0 |
| 30 Jun 23 | 109 | -29 | 59 | 0 |
| 31 Mar 23 | 108 | -23 | 57 | 0 |
| 31 Dec 22 | 108 | -21 | 56 | 0 |
| 30 Sep 22 | 108 | -26 | 53 | 0 |
| 30 Jun 22 | 106 | -27 | 55 | 0 |
| 31 Mar 22 | 108 | -33 | 59 | 0 |
| 31 Dec 21 | 105 | -38 | 58 | 0 |
| 30 Sep 21 | 93 | -54 | 60 | 0 |
| 30 Jun 21 | 82 | -58 | 54 | 0 |
| 31 Mar 21 | 68 | -62 | 49 | 0 |
| 31 Dec 20 | 58 | -60 | 49 | 0 |
| 30 Sep 20 | 50 | -185 | 45 | 0 |
| 30 Jun 20 | 40 | -187 | 47 | 0 |
| 31 Mar 20 | 30 | -183 | 45 | 0 |
| 31 Dec 19 | 19 | -179 | 38 | 0 |
| 30 Sep 19 | 13 | -23 | 31 | 0 |
| 30 Jun 19 | 8 | -14 | 22 | 0 |
| 31 Mar 19 | 6 | -12 | 17 | 0 |
| 31 Dec 18 | 4 | -9 | 13 | 0 |
| 30 Sep 18 | 1 | -9 | 9 | 0 |
| 31 Dec 17 | 1 | -4 | 4 | 0 |
| 31 Dec 16 | 2 | -5 | 15 | 0 |
Quality Earnings: FFNT.F is currently unprofitable.
Growing Profit Margin: FFNT.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FFNT.F is unprofitable, but has reduced losses over the past 5 years at a rate of 32.8% per year.
Accelerating Growth: Unable to compare FFNT.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FFNT.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: FFNT.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.